For example, although angiotensin-converting enzyme (ACE) inhibitors have been considered a standard of care for hypertension in diabetic patients, with no known effects on endothelial fenestrations [94], sodium-glucose cotransporter-2 (SGLT2) inhibitors have recently been identified as a promising therapy to slow DN progression [95]. This evidence concerns the gene SLC5A2 and liver dysplastic nodule.